DrugPatentWatch Database Preview
Lannett Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for LANNETT, and what generic alternatives to LANNETT drugs are available?
LANNETT has one hundred and ninety-six approved drugs.
There is one US patent protecting LANNETT drugs. There is one tentative approval on LANNETT drugs.
There are fifteen patent family members on LANNETT drugs in twelve countries and one hundred and sixty-one supplementary protection certificates in thirteen countries.
Summary for Lannett
| International Patents: | 15 |
| US Patents: | 1 |
| Tradenames: | 144 |
| Ingredients: | 134 |
| NDAs: | 196 |
| Patent Litigation for Lannett: | See patent lawsuits for Lannett |
| PTAB Cases with Lannett as petitioner: | See PTAB cases with Lannett as petitioner |
Drugs and US Patents for Lannett
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett | ACETAZOLAMIDE | acetazolamide | TABLET;ORAL | 084840-001 | Approved Prior to Jan 1, 1982 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lannett Co Inc | LANSOPRAZOLE | lansoprazole | CAPSULE, DELAYED REL PELLETS;ORAL | 207156-001 | Sep 28, 2017 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Lannett Co Inc | PAROXETINE HYDROCHLORIDE | paroxetine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204744-002 | Jun 10, 2016 | AB | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lannett
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lannett Co Inc | MYKROX | metolazone | TABLET;ORAL | 019532-001 | Oct 30, 1987 | 4,517,179 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LANNETT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 10 mg, 20 mg and 30 mg | ➤ Subscribe | 2005-05-13 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-03-15 |
International Patents for Lannett Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 0234234 | Start Trial |
| Hungary | 0303695 | Start Trial |
| Poland | 361673 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lannett Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0268956 | SPC/GB98/040 | United Kingdom | Start Trial | PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508 |
| 1411900 | SPC/GB11/015 | United Kingdom | Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 0509752 | C990041 | Netherlands | Start Trial | PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
